URICARE®
Effervescent Granues
  • URICARE® is  a multifunctional formulation combining three active ingredients with multiple complementary activities on the urinary  tract.
  • Hexamine and Piperazine citrate are rapidly absorbed from the gastrointestinal tract and a great part of them reaches the urine unchanged.
  • Hexamine is rapidly and almost completely eliminated in the urine, where it is slowly hydrolysed in acidic medium  to ammonia and formaldehyde. The half-life is approximately four hours.The peak concentration of formaldehyde is up to 2 hours after administration. The produced formaldehyde has antiseptic effect to which uropathogens are susceptible and do not develop resistance on long  term treatment, those benefit to use for long term treatment.
  • Piperazine citrate which adds to the benefit of URICARE® by increasing uric acid excretion and dissolving urate crystals, and through its acidic nature,it potentiates the antibacterial effect of Hexamine. 
  • Khellin, the third ingredient of plant origin, has a direct powerful and long lasting antispasmodic action on the smooth muscles of the urinary tract.
  • These properties make URICARE® Effervescent Granules a drug of choice with multiple actions and wide  range of safety when used for long term.

Each sachet contains: 

  •   Hexamine              500 mg.
  •   Piperazine citrate    190 mg.
  •   Khellin        1.83 mg.
  • Chronic urinary tract infections including pyelitis,pyelonephritis, cystitis and infections accompanying neurogenic  bladder.
  • Prevention of  re-infection of sterile urine in patients with residual urine accompanying some neurological diseases and with prolonged bladder catheterization.
  • Spasms of the urinary tract and relief of discomfort caused by hypermotility resulting from inflammation as in cystitis, prostatitis, urethritis and urethrocystitis.
  • In prevention of urinay tract lithiasis(uratestones.)
  • Patients with hepatic or renal insufficiency. 
  • Renal or heart  failure and severe dehydration.
  • Metabolic acidosis.
  • Neurological disturbances and epilepsy.
  • Hypertension & edema.
  • Concomitant use of Hexamine and Sulphonamides may increase the risk of crystalluria.
  • The concomitant use of Hexamine with urine alkalinizers including some antacid, potassium- citrate, and diuretics must be avoided because the activation of Hexamine to formaldehyde may be inhibited.
  • It is advised not to  be used during pregnancy, especially in the first trimester unless the treatment is essential.
  • Use with  cautions with breast feeding, mother should breast feed after 8 hours of dosing.

URICARE® is well  tolerated but sometimes may cause:

  • GIT disturbances ( e.g. nausea and vomiting.)
  • In rare case  hypersensitivity reactions (including skin rash & bronchospasm.)
  • Unless otherwise prescribed by  the physician the contents of one or two sachets to be dissolved in half a glass of water and taken three times daily.
  • Overdose may rarely produce nervous complications, especially in patients suffering from disturbance in the renal functions.
  •  Box containing 6 or 12 sachets.
  • Keep in a dry place away from moisture and light at a temperature not more than 25ºC.